Martha Jefferson Hospital offers Xofigo® (radium-223 dichloride), the latest treatment option for men with advanced prostate cancer. Xofigo® is used in treatment for men whose prostate cancer has spread (or metastasized) to their bones.
Xofigo® binds with minerals in the bone allowing for the delivery of radiation directly to bone tumors. By doing this, normal surrounding tissue is spared from significant damage, which is a huge improvement from previous solutions.
Xofigo® is given once a month for six months and is injected into a patient’s vein over one minute. A typical appointment for treatment lasts no longer than fifteen minutes.
“Xofigo is a very important new treatment option for men with prostate cancer bone metastases. It is very effective at relieving bone pain and extends survival. It will allow many men to delay chemotherapy for a significant period of time," commented Dr. Charles Myers Jr., an oncologist with the American Institute for Disease of the Prostate.
Sentara CarePlex Hospital, located in Hampton, VA, was the first facility in Virginia to treat a patient with Xofigo®.